Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.

Miele, L., Napodano, C., Cesario, A., De Magistris, A., Pocino, K., Basile, U., Rapaccini, G. L., Gasbarrini, A., Grieco, A., COVID-19, adaptative immune response and metabolic-associated liver disease, <<LIVER INTERNATIONAL>>, N/A; 41 (11): 2560-2577. [doi:10.1111/liv.15061] [http://hdl.handle.net/10807/206298]

COVID-19, adaptative immune response and metabolic-associated liver disease

Miele, L.
;
Napodano, C.;Cesario, A.;Pocino, K.;Basile, U.;Rapaccini, G. L.;Gasbarrini, A.;
2021

Abstract

Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.
Inglese
Miele, L., Napodano, C., Cesario, A., De Magistris, A., Pocino, K., Basile, U., Rapaccini, G. L., Gasbarrini, A., Grieco, A., COVID-19, adaptative immune response and metabolic-associated liver disease, <<LIVER INTERNATIONAL>>, N/A; 41 (11): 2560-2577. [doi:10.1111/liv.15061] [http://hdl.handle.net/10807/206298]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/206298
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact